O'Connell Kevin Sean, McGregor Nathaniel Wade, Emsley Robin, Seedat Soraya, Warnich Louise
Department of Genetics, Stellenbosch University, Stellenbosch, South Africa.
Department of Psychiatry, Stellenbosch University, Tygerberg, South Africa.
Front Genet. 2019 Jul 10;10:641. doi: 10.3389/fgene.2019.00641. eCollection 2019.
Despite advances in pharmacogenetics, the majority of heritability for treatment response cannot be explained by common variation, suggesting that factors such as epigenetics may play a key role. Regulatory genes, such as those involved in DNA methylation and transcriptional repression, are therefore excellent candidates for investigating antipsychotic treatment response. This study explored the differential expression of regulatory genes between patients with schizophrenia (chronic and antipsychotic-naïve first-episode patients) and healthy controls in order to identify candidate genes for association with antipsychotic treatment response. Seven candidate differentially expressed genes were identified, and four variants within these genes were found to be significantly associated with treatment response ( rs2304429, rs11079983, and rs1178119 and rs11764843). Further analyses revealed that two of these variants (rs2304429 and rs11079983) are predicted to alter the expression of specific genes (, , and ) in brain regions previously implicated in schizophrenia and treatment response. These results may aid in the development of biomarkers for antipsychotic treatment response, as well as novel drug targets.
尽管药物遗传学取得了进展,但治疗反应的大部分遗传力无法用常见变异来解释,这表明表观遗传学等因素可能起关键作用。因此,参与DNA甲基化和转录抑制的调控基因是研究抗精神病药物治疗反应的极佳候选基因。本研究探讨了精神分裂症患者(慢性患者和未使用过抗精神病药物的首发患者)与健康对照之间调控基因的差异表达,以确定与抗精神病药物治疗反应相关的候选基因。鉴定出七个候选差异表达基因,并发现这些基因中的四个变异与治疗反应显著相关(rs2304429、rs11079983、rs1178119和rs11764843)。进一步分析表明,其中两个变异(rs2304429和rs11079983)预计会改变先前与精神分裂症和治疗反应相关的脑区中特定基因(、和)的表达。这些结果可能有助于开发抗精神病药物治疗反应的生物标志物以及新的药物靶点。